View details of this raise on Seedstage

Fremont, CA

Bringing a non-invasive, real-time skin cancer detection device to market.

• Innovative technology: Uses Raman spectroscopy for non-invasive skin cancer detection in under 1.5 seconds.
• Extensive R&D: Developed over 20 years with $20M+ invested by leading institutions.
• Regulatory progress: Passed performance and safety tests; undergoing FDA review.
• Strong IP portfolio: Holds 8 issued patents and exclusive technology licensing rights.
• Experienced leadership: CEO previously scaled a company from startup to NASDAQ listing.

Vita Imaging is developing AURA™, a patented, non-invasive diagnostic device designed to identify skin cancer in under 1.5 seconds. Built on two decades of research and over $20 million in investment from leading institutions, AURA™ uses Raman spectroscopy to detect whether skin lesions are benign or malignant without the need for a biopsy. The device has passed performance and safety testing and is undergoing FDA review, with validation taking place in multi-site clinical studies at Veterans Association hospitals. Designed for use in dermatology and primary care settings, AURA™ aims to provide real-time, accurate detection that could reduce unnecessary procedures and support earlier intervention.

The company holds eight issued patents and exclusive licensing rights to technology from the BC Cancer Agency and University of British Columbia, providing a foundation for expanding into diagnostics for other cancers. Led by an experienced executive team with prior success in scaling companies to public markets, Vita Imaging plans to commercialize AURA™ following FDA clearance. The fundraising will support efforts toward regulatory approval, market launch, and potential global expansion, with the goal of improving accessibility, speed, and accuracy in cancer detection.

Company Info

Vita Imaging develops AURA™, a patented non-invasive device that detects skin cancer in under 1.5 seconds using Raman spectroscopy.

Vita Imaging is a medical technology company developing AURA™, a patented, non-invasive device designed to detect skin cancer in under 1.5 seconds using Raman spectroscopy. Built on 20 years of research and more than $20 million in investment, AURA™ identifies whether a lesion is benign or malignant without the need for a biopsy, anesthesia, or lab analysis. The system delivers real-time diagnostic results, aiming to reduce unnecessary biopsies and improve early cancer detection. AURA™ has passed performance and safety testing, is undergoing FDA review, and has been validated in multi-site clinical studies at Veterans Association hospitals. The technology is supported by eight issued patents and has exclusive licensing rights from the BC Cancer Agency and the University of British Columbia.

Designed for use in dermatology clinics and primary care offices, AURA™ integrates into a three-step workflow, enabling fast, objective results that can improve diagnostic accuracy. Vita Imaging plans to generate revenue through device sales, disposable test equipment, and potential licensing of its proprietary spectral data for AI integration. While skin cancer is the first target application, the platform technology has potential to expand into detection of other cancers, including colon, esophageal, and lung. The company is positioned within the broader cancer diagnostics market, projected to exceed $155 billion by 2030.